On May 15, 2026, Jason V. Coloma, Chief Executive Officer of Maze Therapeutics, Inc., reported the sale of common stock valued at $50,388. This transaction comprised 1,938 shares of the company's common stock, with each share sold at a price of $26.00.
The sales were conducted pursuant to a Rule 10b5-1 trading plan that Coloma had initially adopted on February 6, 2026. Structurally, the shares disposed of originated from two distinct trusts: the Coloma Family Trust and The Coloma 2021 Irrevocable Trust.
- A total of 1,822 shares were sold from the Coloma Family Trust. For this trust, Coloma and his spouse currently serve as co-trustees.
- An additional 116 shares were liquidated from The Coloma 2021 Irrevocable Trust, where Coloma and his spouse also function as co-trustees.
Following the completion of these sales, Coloma's indirect holdings remain substantial. He currently holds 381,073 shares through the Coloma Family Trust and 31,001 shares via The Coloma 2021 Irrevocable Trust.
The company provided clarification regarding the reporting of these stakes. Maze Therapeutics noted that previous Form 3 filings had incorrectly classified these holdings as directly held. This specific Form 4 filing serves to correct and formally restate the proper attribution of his total shares to their respective trusts.
Beyond the insider activity, recent corporate developments at Maze Therapeutics have drawn considerable market attention. The company recently disclosed results from its Phase 2 HORIZON trial. This clinical study evaluated MZE829, an APOL1 inhibitor, in a patient group suffering from chronic kidney disease.
The data presented from the trial indicated a measurable improvement, showing a 35.6% reduction in the urine albumin-to-creatinine ratio across a diverse cohort of patients. This included individuals who were both diabetic and non-diabetic.
Market analysts have responded with generally positive sentiment to these clinical outcomes. Several prominent financial institutions reiterated favorable ratings on Maze Therapeutics, including BTIG, TD Cowen, Raymond James, Truist Securities, and Leerink Partners.
- BTIG maintained a Buy rating while setting a price target of $46.00 for the stock.
- TD Cowen similarly reiterated a Buy rating on MAZE.
- Raymond James issued a Strong Buy rating, establishing a price target of $56.00.
- Truist Securities reaffirmed its Buy rating, setting a price target of $68.00 and citing the trial's positive proof-of-concept data.
- Leerink Partners continued to support Maze Therapeutics with an Outperform rating and assigned a price target of $50.00, emphasizing the encouraging nature of the Phase 2 trial results.
From an investment perspective, analysis from InvestingPro suggests that MAZE may currently be undervalued at its existing levels, with the company scheduled to release earnings results on May 21.
The stock's historical performance shows volatility. While the common stock has declined by 38% year-to-date, it remains significantly higher than its 52-week low of $8.81, having increased by 176% over the past year.